Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Ethic Inc.

Ethic Inc. boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 174,424 shares of the biopharmaceutical company’s stock after acquiring an additional 6,044 shares during the quarter. Ethic Inc.’s holdings in Bristol-Myers Squibb were worth $9,865,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of BMY. Principal Financial Group Inc. boosted its holdings in shares of Bristol-Myers Squibb by 4.4% during the 3rd quarter. Principal Financial Group Inc. now owns 2,458,536 shares of the biopharmaceutical company’s stock worth $127,205,000 after buying an additional 102,790 shares during the period. First Hawaiian Bank increased its holdings in shares of Bristol-Myers Squibb by 3.5% during the fourth quarter. First Hawaiian Bank now owns 50,198 shares of the biopharmaceutical company’s stock worth $2,839,000 after buying an additional 1,675 shares in the last quarter. Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb by 3.3% during the 4th quarter. Legacy Private Trust Co. now owns 9,751 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 310 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Bristol-Myers Squibb by 1.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 354,161 shares of the biopharmaceutical company’s stock valued at $18,324,000 after buying an additional 3,827 shares during the period. Finally, Franklin Street Advisors Inc. NC raised its stake in shares of Bristol-Myers Squibb by 7,223.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 347,402 shares of the biopharmaceutical company’s stock worth $19,649,000 after buying an additional 342,658 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on BMY shares. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Argus raised Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group dropped their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Finally, UBS Group cut their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $46.77 on Friday. The stock has a market cap of $95.18 billion, a P/E ratio of -10.58, a P/E/G ratio of 2.07 and a beta of 0.39. The business’s fifty day moving average is $54.80 and its 200 day moving average is $56.23. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. During the same period last year, the company earned ($4.40) earnings per share. The business’s revenue was down 5.6% on a year-over-year basis. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.30%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 92.88%.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.